Clinical Trial Results:
Randomized, open-label phase 2 study on post-relapse disease-free survival (PRDFS) with the Viscum-album Extract (VA-E) Iscador P or oral Etoposide in spindle-cell bone-sarcoma patients in complete remission after surgery for second relapse.
Summary
|
|
EudraCT number |
2006-002676-18 |
Trial protocol |
IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jun 2022
|
First version publication date |
09 Jun 2022
|
Other versions |
|
Summary report(s) |
Viscum album extract or etoposide in osteosarcom study report summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.